US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Sage Therapeutics, Inc.

< Previous 1 2 3 Next >
News headline image
Sage Therapeutics Announces Second Quarter 2025 Financial Results
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
News headline image
Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
News headline image
Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
News headline image
Sage Therapeutics Announces R&D Leadership Transition
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
News headline image
Sage Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Pipeline and Business Updates
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
News headline image
Sage Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
News headline image
Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen’s Unsolicited Acquisition Proposal
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
News headline image
Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
News headline image
Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
News headline image
Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
News headline image
Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
News headline image
Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development Portfolio
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
News headline image
Sage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
News headline image
Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
News headline image
Sage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
News headline image
Sage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
News headline image
Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor
From Sage Therapeutics, Inc.
Via Business Wire
Tickers BIIB SAGE
News headline image
Sage Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
News headline image
Sage Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
News headline image
Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
News headline image
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
News headline image
Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
News headline image
Sage Therapeutics to Present at Upcoming March Investor Conferences
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
News headline image
Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
News headline image
Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
News headline image
Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
News headline image
Sage Therapeutics Announces Changes to Board of Directors
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
News headline image
Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
News headline image
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
From Sage Therapeutics, Inc.
Via Business Wire
Tickers BIIB SAGE
News headline image
Sage Therapeutics to Present at Upcoming November Investor Conferences
From Sage Therapeutics, Inc.
Via Business Wire
Tickers SAGE
< Previous 1 2 3 Next >